Elicio reports Q2 2026 results, plans new Phase 1 combination trial after complete responses

Elicio Therapeutics reported financial results for the quarter ended June 30, 2026, on August 13, 2026, alongside a set of pipeline updates. The company disclosed multiple complete responses in patients with metastatic mKRAS pancreatic cancer who received ELI-002 7P followed by checkpoint inhibition, which it said supports a planned Phase 1 combination study.¹ That new study will test ELI-002 7P together with a RAS small molecule inhibitor, with or without an anti-PD-1 inhibitor, in patients with metastatic pancreatic cancer, and is expected to start in the fourth quarter of 2026.¹

Separately, the Phase 2 AMPLIFY-7P trial of ELI-002 7P in adjuvant mKRAS-driven pancreatic cancer did not meet its primary endpoint, though Elicio is still reviewing pre-specified subgroups, including the R0 resected population, to help shape a Phase 3 plan for adjuvant disease.¹ At the time of that Phase 2 analysis, overall survival data were not yet mature.¹

On the regulatory and academic front, a Memorial Sloan Kettering Cancer Center-led, investigator-initiated Phase 1 trial combining ELI-002 7P with chemotherapy and an anti-PD-1 checkpoint inhibitor in borderline resectable and resectable pancreatic ductal adenocarcinoma has been activated, funded through a partnership between The Lustgarten Foundation and Break Through Cancer.¹

On financing, Elicio completed a $15.0 million registered direct offering led by new institutional investors to fund the planned Phase 1 metastatic pancreatic cancer study and broader pipeline work.¹ The company held $23.5 million in cash as of June 30, 2026, which it expects will fund operations into the first quarter of 2027.¹ Net loss for the quarter was $8.2 million, versus $10.6 million a year earlier.¹